Capricor疗法 CAPR 深 沪
已收盘 05-08 16:00:00 美东时间
30.38
-3.560
-10.49%
华盛通- 最 高31.275
- 今 开29.50
- 成交量 370.86万股
- 最 低 28.45
- 昨 收 33.94
- 总市值 17.57亿
- 52周最高 40.37
- 市盈率 静 --
- 换手率 6.41%
- 52周最低 4.30
- 委 比 22.03%
- 总股本 5784.01万
- 历史最高 171.50
- 量 比 3.82
- 振 幅 8.32%
- 历史最低 0.88
- 每 手 1
- 风险率 10.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor drops following filing of lawsuit against Nippon Shinyaku
Capricor Therapeutics (CAPR) is down ~11% in Friday trading after announcing following Thursday's market close it is suing Nippon Shinyaku due to a "fundamental pricing flaw" in an agreement the two c...
05-09 03:02
Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002
Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002 Nippon Shinyaku faces lawsuit filed May 7, 2026 in New Jersey Superior Court, Chancery Division, Bergen County by Capricor Therapeutics seeking injunction tied to commercialization and distribution agreement for CAP-1002 (deramio
05-08 16:33
Capricor Sues NS Pharma Over Deramiocel U.S. Rights
The latest update is out from Capricor Therapeutics ( ($CAPR) ). On May 7, 2026...
05-08 07:15
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics will release its Q1 2026 financial results on May 12, 2026, after market close. Management will host a conference call and webcast at 4:30 p.m. ET that day. Participants can join via phone or webcast using the provided details. The company, focused on developing cell and exosome-based therapies for rare diseases, recently advanced its lead candidate, Deramiocel, for Duchenne muscular dystrophy. A replay of the call will be a...
05-04 20:05
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
Capricor Therapeutics announced the presentation of Phase 3 HOPE-3 trial data for Deramiocel in Duchenne muscular dystrophy (DMD) at the 2026 AAN Annual Meeting. The data showed statistically and clinically meaningful improvements in upper limb function and slowing of disease progression, highlighting Deramiocel's potential as a transformative therapy. The company emphasized its commitment to the DMD community and noted that the BLA for Deramioce...
04-22 13:00
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x
A Bank of America Global Research chart tracking healthcare R&D-to-sales ratios and relative forward PE versus the S&P 500 from 1990 to March 2026 shows both metrics declining in tandem over decades, ...
04-17 04:04
Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million
Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million Capricor Therapeutics director Sabar Karimah Es sold 115,000 shares in transactions dated March 31, 2026 and April 1, 2026. Sales were executed at weighted average prices of $30.17 and $31.03 per share. Es reported 0 sha
04-02 08:00
Capricor EVP, General Counsel Karen Krasney disposes of CAPR shares worth $0.8 million
Capricor EVP, General Counsel Karen Krasney disposes of CAPR shares worth $0.8 million Capricor Therapeutics EVP, General Counsel Karen Krasney sold 25,000 shares on March 31, 2026 at weighted average price of $30.12. Krasney exercised stock options for 24,000 shares on March 31, 2026 at prices rang
04-02 08:00
Capricor CFO Anthony Bergmann disposes of $0.8 million in common shares
Capricor CFO Anthony Bergmann disposes of $0.8 million in common shares Capricor CFO Anthony Bergmann reported sale of 25,000 shares on March 31. Disposition priced at USD 30.13 per share on weighted-average basis. Filing also showed exercise of options for 25,000 shares at USD 3.18 per share. Holdi
04-02 08:00
财报速睇 | Capricor疗法 2025财年年度营收0.00亿美元，同比下降100.0%；归母净利润亏损1.05亿美元，同比亏损扩大159.6%
华盛资讯3月18日讯，Capricor疗法公布2025财年年度业绩，公司年度营收0.00亿美元，同比下降100.0%，归母净利润亏损1.05亿美元，同比亏损扩大159.6%。
03-18 07:17
